Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Treasury Shares (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Treasury Shares for 1 consecutive years, with $53.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $53.2 million, compared with a TTM value of $53.2 million through Dec 2025, changed N/A, and an annual FY2025 reading of $53.2 million, changed N/A over the prior year.
  • Treasury Shares was $53.2 million for Q4 2025 at Arrowhead Pharmaceuticals, roughly flat from $53.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.1 million in Q1 2024 and bottomed at $183750.0 in Q4 2024.
  • Average Treasury Shares over 5 years is $3.6 million, with a median of $3.9 million recorded in 2025.
  • The sharpest move saw Treasury Shares crashed 95.99% in 2024, then skyrocketed 1348.16% in 2025.
  • Year by year, Treasury Shares stood at $3.6 million in 2021, then increased by 10.63% to $4.0 million in 2022, then rose by 15.65% to $4.6 million in 2023, then plummeted by 95.99% to $183750.0 in 2024, then surged by 1348.16% to $2.7 million in 2025.
  • Business Quant data shows Treasury Shares for ARWR at $2.7 million in Q4 2025, $2.7 million in Q3 2025, and $3.9 million in Q2 2025.